Introduction {#s1}
============

Since the outbreak of COVID-19 in Wuhan, Hubei province, in December 2019, it has had a major impact on people\'s lives, health, and property safety. It has rapidly expanded to 34 provincial divisions of China ([@B2]--[@B4]). As of April 28, 2020, the total number of confirmed cases in Wuhan has reached 68,128, accounting for 80.75% of the total number of confirmed cases in China, and 4,512 people have died in Wuhan, accounting for 97.18% of the total number of deaths in China ([@B5]).

SARS-CoV-2 is a binuclear virus that has a wide clinical spectrum of infection ([@B6]--[@B8]). In the past 2 months, only a few studies have analyzed prognostic factors for death, with repeated emphasis on factors such as age, lymphocytosis, leukocytosis, and elevated ALT ([@B7]). Thus, some of these potential prognostic factors need further validation, and a scoring system that accurately predicts the possible mortality risk is needed. Nomograms are used for multiple indicators to diagnose or predict disease onset or progression, making prognostic model results easier to read. Therefore, nomograms have been gradually applied in medical research and clinical practice ([@B9], [@B10]).

Here, we randomly selected some patients with definite clinical outcome (death or discharge) who had been admitted to the critical care unit of the Optical Valley Branch of Tongji Hospital, Huazhong University of Science and Technology, as of March 10, 2020 ([@B11]). The aim of our study was to establish a nomogram that incorporated demographics, clinical characteristics, and laboratory results to predict individual mortality in COVID-19 patients.

Materials and Methods {#s2}
=====================

Patient Selection
-----------------

We selected COVID-19 patients admitted to the critical illness area of the Optical Valley Branch of Tongji Hospital, Huazhong University of Science and Technology, from February 9, 2020, to March 10, 2020.

Patients were enrolled in this cohort if they: (1) were more than 18 years old; (2) were diagnosed with COVID-19 by multiplex real-time RT-PCR; (3) had complete clinical records of medical history and laboratory results. Patients were excluded if they: (1) were suspected with COVID-19; (2) had incomplete clinical records of medical history and laboratory results.

Study Variables
---------------

We collected demographics, comorbidities, routine laboratory tests, immunological indicators, radiological images, and inpatient treatments ([@B12]). For each patient, the baseline characters were screened: gender, age, leukocytes, platelet--lymphocyte ratio (PLR), neutrophil--lymphocyte ratio (NLR), Charlson Comorbidity Index (CCI), CURB-65 score, PaO~2~/FiO~2~, interleukin-1β (IL-1β), interleukin-2R (IL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), cardiac troponin I (cTnI), brain natriuretic peptide (BNP), calcitonin, c-reactive protein (CRP), lactate dehydrogenase (LDH), d-dimer, fibrinogen, history of hypertension, heart failure, coronary heart disease (CHD), diabetes, cough, expectoration, diarrhea, shortness of breath, body temperature above 38°C, and X-ray or CT findings.

Construction of the Nomogram
----------------------------

We used the chi-square test for univariate analysis. Multivariable regression models were developed by incorporating meaningful factors in univariate analyses. Univariate and multivariate regression analysis was used to analyze the risk factors in the primary cohort ([@B13]). Then we construct a nomogram on the basis of the multivariate logistic regression model.

Statistical Analysis
--------------------

Patients\' demographic and clinical characteristics were analyzed using descriptive methods, with standard summary statistics including the median, interquartile range (IQR), and proportions. Categorical variables were processed by Chi-square or Fisher\'s exact tests, as appropriate. We tested the accuracy of the nomograms by discrimination and calibration both in the primary and the validation cohort. We used the receiver operating characteristic curve (ROC) to assess the discriminative ability of the nomogram and then assessed the area under the curve (AUC) ([@B14], [@B15]). Calibration curves were used to compare the association between actual outcomes and predicted probabilities ([@B16]). Decision curve analysis (DCA) was performed by calculating the net benefits for a range of threshold probabilities to evaluate the clinical utility of the nomogram ([@B17], [@B18]). Statistical analysis was performed using SPSS 23 (IBM, Chicago, IL, USA) and R version 3.4.4. All statistical tests were two-tailed, and a *P* \< 0.05 was considered to be statistically significant.

Results {#s3}
=======

Patient Characteristics
-----------------------

Between February 9, 2020, and March 10, 2020, from more than 600 patients in the critical illness area of the Optical Valley Branch of Tongji Hospital, 120 cases were selected for inclusion in the study by means of a random number table. The average age of the 120 patients was 62.16 years old, and there were 50 females and 70 males ([@B19]). The majority of the patients were over 60 years old (69.20%). Among the 120 cases, 90 (75.0%) developed cough symptoms with or without expectoration, 62 (51.7%) had high fever (≥38°C), 68 (56.7%) had mild shortness of breath, and 15 (12.5%) developed diarrhea. The vast majority of patients exhibited bilateral invasion in chest X-ray and CT, mostly with a patchy and ground-glass appearance ([Table 1](#T1){ref-type="table"}).

###### 

Results of the univariate association analyses.

  **Characteristics**   **Death set**             **Survival set**          ***Z*-value**   ***P*-value**
  --------------------- ------------------------- ------------------------- --------------- ---------------
  Age, year             70 (66, 78.5)             64 (51, 70)               −3.273          0.001
  Sex (male)            17                        53                        5.358           0.021
  Sex (female)          4                         46                                        
  WBC                   9.01 (5.42, 14.62)        5.47 (4.49, 6.81)         −3.398          0.001
  NLR                   10.44 (5.70, 25.10)       2.50 (1.80, 3.84)         −5.688          0.000
  PLR                   305.88 (143.23, 352.80)   204.40 (149.43, 312.73)   −1.433          0.152
  PCT                   0.29 (0.15, 0.57)         0.06 (0.05, 0.07)         −6.560          0.000
  CRP                   113.3 (63.55, 145.4)      8.9 (2.4, 32.4)           −5.888          0.000
  LDH                   566 (327.5, 667.5)        245 (190, 285)            −5.046          0.000
  Fibrinogen            4.9 (3.22, 6.19)          5.18 (4.1, 5.85)          −0.597          0.550
  PaO~2~/FiO~2~         105.43 (76.05, 161.98)    331.76 (233.89, 390.54)   −6.351          0.000
  Serumcalcium(L)       19                        77                        1.043           0.307
  TNI(H)                11                        5                         29.615          0.000
  BNP(H)                18                        23                        30.070          0.000
  CURB-65(0--1)         10                        93                        26.879          0.000
  CURB-65(2--5)         11                        6                                         
  CCI index(0--2)       18                        96                        2.555           0.110
  CCI index(3-)         3                         3                                         
  IL-1β(H)              4                         16                        0.000           1.000
  IL-2R(H)              17                        34                        15.554          0.000
  IL-6(H)               19                        36                        20.434          0.000
  IL-8(H)               4                         4                         4.091           0.043
  IL-10(H)              8                         8                         11.034          0.001
  TNF-α(H)              16                        45                        6.549           0.010
  D-dimer(H)            21                        68                        8.866           0.003
  Hypertension          13                        31                        6.982           0.008
  Heart failure         1                         0                                         0.175
  CHD                   4                         5                         3.083           0.079
  Diabetes              4                         14                        0.055           0.814
  Cough                 14                        76                        0.943           0.332
  Expectoration         7                         44                        0.875           0.350
  Diarrhea              2                         13                        0.008           0.928
  ≥38°C                 11                        51                        0.005           0.943
  GGO                   8                         30                        0.486           0.486
  Consolidation         0                         13                        1.883           0.170
  Pathy                 15                        77                        0.116           0.733
  Fibrosis              0                         3                                         1.000

Independent Prognostic Factors
------------------------------

We used univariate and multivariate analyses to identify the prognostic factors ([@B20], [@B21]). The univariate analysis revealed that age (*p* = 0.001), Male/Female (*p* = 0.021), WBC (*p* = 0.001), NLR (*p* = 0.000), PCT (*p* = 0.000), CRP (*p* = 0.000), LDH (*p* = 0.000), PaO~2~/FiO~2~ (*p* = 0.000), Serum calcium (*p* = 0.307), cTnI (*p* = 0.000), BNP (*p* = 0.000), CURB-65 (*p* = 0.000), IL-2R (*p* = 0.000), IL-6 (*p* = 0.000), IL-8 (*p* = 0.043), IL-10 (*p* = 0.001), TNF-α (*p* = 0.01), D-dimer (*p* = 0.003), and Hypertension (*p* = 0.008) were significant prognostic factors. The multivariate analysis revealed that CRP (*p* = 0.004), PaO~2~/FiO~2~ (*p* = 0.002), and cTnI (*p* = 0.016) were independent prognostic factors for predicting the mortality of COVID-19 patients ([@B22]).

Development and Validation of a Nomogram
----------------------------------------

Multivariate logistic regression analysis determined that CRP, PaO~2~/FiO~2~, and cTnI were independent predictors ([Table 2](#T2){ref-type="table"}). The model with three independent predictors is established and represented by a nomogram ([Figure 1](#F1){ref-type="fig"}).

###### 

Multivariate logistic regression of death in COVID-19 patients.

              **B**    **SE**   **Wald**   **OR(95%CI)**              ***P*-value**
  ----------- -------- -------- ---------- -------------------------- ---------------
  CRP         0.037    0.013    8.271      1.037 (1.012, 1.064)       0.004
  PaO2/FiO2   −0.045   0.015    9.144      0.956 (0.929, 0.984)       0.002
  TNI         5.417    2.244    5.830      225.296 (2.773, 18303.1)   0.016

![Nomogram predicting mortality for COVID-19 patients with three available factors: CRP, PaO~2~/FiO~2~, and cTnI.](fpubh-08-00461-g0001){#F1}

We predicted the probability of death in patients with COVID-19 by calculating the sum of points in the nomogram corresponding to patient characteristics. Regarding the clinical application of this nomogram, we assumed that, if a patient\'s CRP was 20 mg/L, the PaO~2~/FiO~2~ was 350, and the cTnI was increased, then the corresponding score of this patient was 3+33+26, a total of 62 points, so the corresponding risk of death of this patient was between 0.001 and 0.01, and this patient was relatively safe.

The AUC for the prediction nomogram was 0.988, 95% CI, 0.972--1.000 ([@B23]). The AUC for CRP was 0.910. The AUC for PaO~2~/FiO~2~ was 0.942. The AUC for cTnI was 0.737. The nomogram decision curve analysis is shown in [Figure 2](#F2){ref-type="fig"}. The calibration curve of the nomogram for the probability of mortality demonstrated good agreement between prediction and observation in the primary cohort ([Figure 2](#F2){ref-type="fig"}) ([@B24]). The decision curve showed that if the threshold probability of a patient or doctor is \>0%, using the nomogram to predict the mortality for COVID-19 patients adds more benefit. Within this range, net benefit was comparable, with several overlaps, on the basis of the nomogram ([@B25]).

![From left to right: ROC curves of the nomogram and the three factors; calibration curve of the nomogram in the cohort; decision curve analysis for the nomogram. The y-axis measures the net benefit. The red line represents the nomogram. The gray line represents the assumption that all patients have died. The thin black link represents the assumption that no patients have died. The net benefit was calculated by subtracting the proportion of all patients who are false positive from the proportion who are true positive, weighting by the relative harm of forgoing treatment compared with the negative consequences of unnecessary treatment.](fpubh-08-00461-g0002){#F2}

Validation was performed by using another 84 COVID-19 patients. In the validation cohort, the independent risk factors included in the nomogram were examined. The AUC of the nomogram was 0.956 (95% CI: 0.874--1.000). [Figure 3](#F3){ref-type="fig"} shows that the calibration plot for the probability of mortality demonstrated good agreement between the prediction by nomogram and actual observation.

![From left to right: ROC curves of the Nomogram and the three factors; calibration curve of the nomogram in the cohort; decision curve analysis for the nomogram.](fpubh-08-00461-g0003){#F3}

Discussion {#s4}
==========

Since 2003, coronavirus has caused a number of major public health events ([@B26], [@B27]). Generally, it was not until the outbreak of severe acute respiratory syndrome (SARS) in Guangdong, China, in 2002 and 2003 that the coronavirus was found to be highly pathogenic to humans. Another highly pathogenic coronavirus is the Middle East respiratory syndrome (MERS) coronavirus, which emerged in 2012 in Middle Eastern countries ([@B28]--[@B31]). COVID-19 is another highly pathogenic coronavirus that has been added to human history. Although COVID-19 has a mortality rate of \<3% compared to SARS (9.6%) and MERS (34%), its effects remain extremely sudden and devastating ([@B32], [@B33]).

Previous studies have shown that coronaviruses can cause respiratory and intestinal infections ([@B34]). According to recent reports, the most common symptoms of COVID-19 patients are fever, cough, myalgia, and fatigue, while the less common are expectoration, hemoptysis, and diarrhea ([@B35]--[@B39]). Most patients have mild symptoms and good prognosis. Mild patients may have only a low fever and mild weakness, with no obvious signs of pneumonia ([@B40]). In the late stage of infection, a variety of complications occur in critically ill patients, including ARDS, septic shock, refractory metabolic acidosis, acute myocardial injury, disseminated intravascular coagulation, and even death ([@B5], [@B6]). Therefore, early diagnosis and early assessment of the patient\'s prognosis are crucial for controlling the outbreak.

Corticosteroids were used extensively during the outbreaks of severe SARS and MERS and are being applied in COVID-19 patients. Corticosteroids suppress inflammation in the lungs but also inhibit immune responses and pathogen clearance at the same time ([@B41]). The clinical benefit of corticosteroids in COVID-19 needs further clinical trials to confirm ([@B42], [@B43]).

In previous studies, several prognostic models have been developed. For example, the NLR was the most effective prognostic factor affecting prognosis for severe COVID-19 patients ([@B44]).

In our study, this nomogram based on three variables, CRP, PaO~2~/FiO~2~, and cTnI, can provide a more accurate assessment and prediction of mortality at admission for COVID-19 patients. If patients with high mortality rates are properly and promptly identified, they should be more likely to benefit from nutritional support in nursing care and close attention in clinical care, which will ultimately have a positive impact on their recovery ([@B45], [@B46]).

The variables in the nomogram we constructed were easily accessible from routine clinical work. As a result, clinicians can use this simple, intuitive predictive tool to draw a few lines in a few seconds to make a quick assessment of a patient\'s prognosis with no computational difficulty. Additionally, our model can help clinical workers rationally allocate medical resources to reduce the fatality rate of COVID-19 when medical resources are scarce.

There are still some limitations to our study. First, the study was at a single center with a small sample, and the next step is to include as many cases as possible from multiple centers to build a more reliable predicting nomogram for mortality in COVID-19 patients. Second, we excluded patients whose case data were incomplete, which could have resulted in selection bias.

Conclusions {#s5}
===========

To sum up, to better identify the prognosis of COVID-19 patients, identify severe patients as early as possible, improve the cure rate, and reduce the fatality rate, we constructed a nomogram based on 120 patients to predict mortality. The proposed nomogram considered three independent risk factors, namely, CRP, PaO~2~/FiO~2~, and cTnI. We have confirmed that this nomogram has excellent discrimination and clinical availability.
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